High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study.
CyberKnife
Early-stage lung cancer
Local control
Radiation pneumonitis
Stereotactic body radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
19 Jul 2022
19 Jul 2022
Historique:
received:
19
05
2022
accepted:
29
06
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung cancer (NSCLC). Ninety-six patients with stage I peripheral NSCLC who were treated with SBRT using a CyberKnife® from August 2010 to June 2019 were identified and included in this study. Local control (LC), local progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS), and late toxicity were evaluated. Potential risk factors associated with LC, LPFS, PFS, or OS were investigated by univariate analyses. Data of 96 patients were examined. The prescribed dose to the tumor was 54 Gy in 3 fractions in 91 patients and 60 Gy in 3 fractions in 5 patients. The median follow-up duration was 27 months. The 2-year LC, LPFS, PFS, and OS rates were 97%, 88%, 84%, and 90%, respectively. The T factor was significantly correlated with LC, LPFS, and PFS. The 2-year LC rate for patients with T1a/T1b and T1c/T2a disease was 100% and 90%, respectively (p < 0.05), and the 2-year PFS rate for the corresponding patients was 95% and 65%, respectively (p < 0.001). One patient (1%) developed grade 3 radiation pneumonitis. High-dose SBRT using a CyberKnife® for stage I peripheral NSCLC produced favorable treatment outcomes with acceptable late toxicity. Further studies are needed to improve the treatment outcomes for patients with T1c/T2a disease.
Sections du résumé
BACKGROUND
BACKGROUND
This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung cancer (NSCLC).
METHODS
METHODS
Ninety-six patients with stage I peripheral NSCLC who were treated with SBRT using a CyberKnife® from August 2010 to June 2019 were identified and included in this study. Local control (LC), local progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS), and late toxicity were evaluated. Potential risk factors associated with LC, LPFS, PFS, or OS were investigated by univariate analyses.
RESULTS
RESULTS
Data of 96 patients were examined. The prescribed dose to the tumor was 54 Gy in 3 fractions in 91 patients and 60 Gy in 3 fractions in 5 patients. The median follow-up duration was 27 months. The 2-year LC, LPFS, PFS, and OS rates were 97%, 88%, 84%, and 90%, respectively. The T factor was significantly correlated with LC, LPFS, and PFS. The 2-year LC rate for patients with T1a/T1b and T1c/T2a disease was 100% and 90%, respectively (p < 0.05), and the 2-year PFS rate for the corresponding patients was 95% and 65%, respectively (p < 0.001). One patient (1%) developed grade 3 radiation pneumonitis.
CONCLUSIONS
CONCLUSIONS
High-dose SBRT using a CyberKnife® for stage I peripheral NSCLC produced favorable treatment outcomes with acceptable late toxicity. Further studies are needed to improve the treatment outcomes for patients with T1c/T2a disease.
Identifiants
pubmed: 35854333
doi: 10.1186/s13014-022-02094-3
pii: 10.1186/s13014-022-02094-3
pmc: PMC9297648
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128Informations de copyright
© 2022. The Author(s).
Références
Technol Cancer Res Treat. 2015 Dec;14(6):667-76
pubmed: 24988054
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1241-56
pubmed: 15519797
Clin Oncol (R Coll Radiol). 2001;13(2):71-81
pubmed: 11373882
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e305-16
pubmed: 21658853
Strahlenther Onkol. 2018 Feb;194(2):91-97
pubmed: 28812120
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):462-469
pubmed: 29353658
Radiother Oncol. 2009 Jun;91(3):296-300
pubmed: 19297048
JAMA Oncol. 2018 Sep 1;4(9):1263-1266
pubmed: 29852037
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-11
pubmed: 25052562
J Thorac Oncol. 2016 Oct;11(10):1653-71
pubmed: 27364315
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):344-50
pubmed: 25636759
Cancer. 2004 Oct 1;101(7):1623-31
pubmed: 15378503
Chest. 2013 May;143(5 Suppl):e1S-e29S
pubmed: 23649439
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):989-96
pubmed: 26581137
Expert Rev Med Devices. 2012 Sep;9(5):465-75
pubmed: 23116073
Technol Cancer Res Treat. 2012 Jun;11(3):249-55
pubmed: 22417057
J Radiat Res. 2013 Jan;54(1):140-5
pubmed: 22951318
J Thorac Oncol. 2019 Apr;14(4):583-595
pubmed: 30721798
J Natl Compr Canc Netw. 2022 May;20(5):497-530
pubmed: 35545176
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1104-11
pubmed: 20472343
Pract Radiat Oncol. 2012 Oct-Dec;2(4):288-295
pubmed: 24674167
Front Oncol. 2015 Jun 30;5:146
pubmed: 26175966